Loading...
•
Mar 31, 2021
United Therapeutics Q1 2021 Earnings Report
United Therapeutics reported financial results for Q1 2021, which included FDA approval of Tyvaso for PH-ILD and submission of the Tyvaso DPI NDA.
Key Takeaways
United Therapeutics reported a 6% year-over-year increase in total revenue, reaching $379.1 million in the first quarter of 2021. The company also saw net income decrease by 79% to $28.3 million, and non-GAAP earnings increased by 2% to $162.1 million.
Total revenue grew 6% year-over-year to $379.1 million.
Net income decreased 79% to $28.3 million.
Non-GAAP earnings increased 2% to $162.1 million.
Tyvaso approved for pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Revenue by Segment
Forward Guidance
United Therapeutics is focused on obtaining the necessary approvals to launch Tyvaso DPI and the Implantable System for Remodulin, and is progressing with research and development plans related to the PERFECT and TETON studies of Tyvaso, the ADVANCE studies of ralinepag, and organ transplantation programs.
Positive Outlook
- Recent launches of Remunity Pump for Remodulin and Tyvaso for patients with PH-ILD.
- Efforts to obtain approvals to launch Tyvaso DPI.
- Ongoing research and development plans related to the PERFECT and TETON studies of Tyvaso.
- ADVANCE studies of ralinepag.
- Organ transplantation programs.
Challenges Ahead
- Risk that the company will not obtain the necessary FDA approvals to launch the products expected to launch in 2021.
- Uncertainties related to the timing and success of efforts to launch Tyvaso DPI.
- Dependence on Medtronic satisfying various conditions to its PMA approval for Implantable System for Remodulin (ISR).
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...